Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score

References

• Delforge M, Bladé J, Dimopoulos M, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086–1095.
   PubMed Web of Science ®Google Scholar
• Richardson P, Hideshima T, Anderson K. Bortezomib (PS – 341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361–369.
   PubMedGoogle Scholar
• Russo A, Bronte G, Fulfaro F, et al. Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets 2010;10:55–67.
   PubMed Web of Science ®Google Scholar
• Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappa B modulation as a therapeutic approach in hematologic malignancies. Cancer 2004;100:1578–1589.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114:1046–1052.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature. Blood 2008;112:1593–1599.
   PubMed Web of Science ®Google Scholar
• Mujtaba T, Don QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011;12:471–480.
   PubMed Web of Science ®Google Scholar
• Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660–1664.
   PubMed Web of Science ®Google Scholar
• Wampler M, Miaskowski C, Hamel K, et al. The modified total neuropathy score: a clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. J Support Oncol 2006;4:9–16.
   Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007; 12:210–215.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006;11:135–141.
   PubMed Web of Science ®Google Scholar
• Miguel JS, Bladé J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51–61.
   Google Scholar
• Anderson KC, Kyle RA, Dalton WS, et al. Multiple myeloma: new insights and therapeutic approaches. Hematology Am Soc Hematol Educ Program 2000:147–165.
   Google Scholar
• Kyrtsonis M-C, Maltezas D, Koulieris E, et al. Response to bortezomib in refractory/relapsed multiple myeloma patients: a single center experience with discussion on specific issues. Asia-Pacific J Oncol Hematol 2010;2:1–11.
   Google Scholar
• Hermans G, Clerckx B, Vanhullebusch T, et al. Interobserver agreement of Medical Research Council sum-score and handgrip strength in the intensive care unit. Muscle Nerve 2012;45:18–25.
   PubMed Web of Science ®Google Scholar
• Khoiny AS, Behrouz R. Critical illness polyneuropathy and criticall illness myopathy. Pract Neurol 2011;11:52–56.
   Google Scholar
• Meijer JW, Smit AJ, Lefrandt JD, et al. Back to basics in diagnosing diabetic polyneuropathy with the tuning fork. Diabetes Care 2005; 28:2201–2205.
   PubMed Web of Science ®Google Scholar
• Devi P, Madhu K, Ganapathy B, et al. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol 2012;4: 51–56.
   Google Scholar
• Matsuoka H, Makimura C, Koyama A, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res 2012;32:1805–1809.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification and management. Am J Hematol 2012;87:78–88.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005;104:2141–2148.
   PubMed Web of Science ®Google Scholar
• Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110:1042–1049.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007; 92:1308–1310.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10:3839–3852.
   PubMed Web of Science ®Google Scholar
• Silverman LCL, Kadambi VJ, Decoster R, et al. Model for proteasome inhibition associated peripheral neuropathy. Toxicol Pathol 2006;34:989.
   Web of Science ®Google Scholar
• Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317–325.
   PubMed Web of Science ®Google Scholar
• Landowski TH, Megli CJ, Nullmeyer KD, et al. Mitochondrial-mediated dysregulation of Ca+2 is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828–3836.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Marmiroli P. The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity. Curt Drug Saf 2006;1:35–42.
   PubMedGoogle Scholar
• Lindsay RM. Nerve growth factors (NGF, BDNF) enhance axonal regeneration but are not required for survival of adult sensory neurons. J Neurosci 1988;8:2394–2405.
   PubMed Web of Science ®Google Scholar
• Weerasuriya A, Mizisin AP. The blood-nerve barrier: structure and functional significance. Methods Mol Biol 2011;686:149–173.
   PubMedGoogle Scholar
• Abe M, Sano Y, Maeda T, et al. Establishment and characterization of human peripheral nerve microvascular methods. Mol Biol 2011;686:149–173.
   Google Scholar
• England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005;64:199–207.
   PubMed Web of Science ®Google Scholar
• Carozzi VA, Canta A, Oggioni N, et al. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 2010;226:301–309.
   Google Scholar
• Giannoccaro MP, Donadio V, Gomis ref65Pèrez C, et al. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurol Sci 2011;32:361–363.
   PubMed Web of Science ®Google Scholar
• Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007;8:296–306.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma:efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518–3525.
   PubMed Web of Science ®Google Scholar
• Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95:311–319.
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008;13:275–282.
   PubMed Web of Science ®Google Scholar
• Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002;13:1636–1640.
   PubMed Web of Science ®Google Scholar
• Huynh W, Kiernan MC. Nerve conduction studies. Aust Fam Physician 2011;40:693–697.
   PubMed Web of Science ®Google Scholar
• Rosenberg NR, Portegies P, de Visser M, et al. Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatry 2001;71:205–209.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–3120.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23–31.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570–1575.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431–400.
   PubMed Web of Science ®Google Scholar
• Mateos MV. Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol 2011;12:410–411.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745–4753.
   PubMed Web of Science ®Google Scholar
• Velasco R, Petit J, Clapés V, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripheral Nerv Syst 2010;15:17–25.
   PubMed Web of Science ®Google Scholar